Does a new mRNA vaccine hold promising results for high-risk melanoma patients?

Melanoma is the most serious and deadliest type of skin cancer. Nearly 1.5 million Americans live with melanoma today. Results from an ongoing clinical trial that personalizes the melanoma vaccine to each patient are showing promising long-term outcomes. Patients with high-risk melanoma who received the mRNA vaccine with the immunotherapy Keytruda cut the risk of the cancer returning by nearly half. Researchers are now looking at whether a similar approach could help treat other types of cancer. Kyle Holen, M.D., the SVP & Head of Development, Oncology and Therapeutics at Moderna, joins Newell to break down how the approach works and who could benefit.